Exacerbations · patients with chronic obstructive pulmonary disease
Tiotropium + LABA/ICS combination showed no clear difference in exacerbation ‐ at 12‐month compared with tiotropium (low certainty).
1 finding from 1 review
Non‐fatal serious adverse events · patients with chronic obstructive pulmonary disease
Tiotropium + LABA/ICS combination showed no clear difference in serious adverse events (non‐fatal) compared with tiotropium (low certainty).
1 finding from 1 review
Quality of life St George's Respiratory Questionnaire (SGRQ) score · patients with chronic obstructive pulmonary disease
1 finding from 1 review
FEV1 · patients with chronic obstructive pulmonary disease
1 finding from 1 review
FEV1 pre‐dose ‐ FEV1 1 year · patients with chronic obstructive pulmonary disease
1 finding from 1 review
no estimate extracted
1 study · 1 participants
Moderate
Intervention not reported
Exacerbations requiring oral corticosteroids 48 weeks · adults with asthma
The intervention showed no clear difference in exacerbations requiring oral corticosteroids 48 weeks (moderate certainty).
1 finding from 1 review
Intervention not reported
Quality of life (AQLQ) · adults with asthma
1 finding from 1 review
Intervention not reported
Serious adverse events 49 weeks · adults with asthma
The intervention showed no clear difference in serious adverse events 49 weeks (low certainty).
1 finding from 1 review
Intervention not reported
Exacerbations requiring hospital admission 49 weeks · adults with asthma
The intervention showed no clear difference in exacerbations requiring hospital admission 49 weeks (low certainty).
1 finding from 1 review
Intervention not reported
Lung function (change in trough FEV1 L) · adults with asthma
1 finding from 1 review
Intervention not reported
Asthma control (ACQ) · adults with asthma
1 finding from 1 review
Intervention not reported
Any adverse events 49 weeks · adults with asthma
The intervention leads to lower any adverse events 49 weeks (high certainty).
1 finding from 1 review
Intervention not reported
Number of participants with exacerbations requiring systemic steroids · children with chronic asthma
The intervention showed no clear difference in number of participants with exacerbations requiring systemic steroids (moderate certainty).
1 finding from 1 review
Intervention not reported
Serious adverse events · children with chronic asthma
The intervention showed no clear difference in serious adverse events (moderate certainty).
1 finding from 1 review
Intervention not reported
Total number of withdrawals · children with chronic asthma
The intervention showed no clear difference in total number of withdrawals (moderate certainty).
1 finding from 1 review
Intervention not reported
Change in FEV1 (L) at endpoint · children with chronic asthma
1 finding from 1 review
Intervention not reported
Change in morning PEF (L/min) at endpoint · children with chronic asthma
1 finding from 1 review
Intervention not reported
Total number of adverse events · children with chronic asthma
The intervention showed no clear difference in total number of adverse events (high certainty).
1 finding from 1 review
Intervention not reported
Number of participants with exacerbations requiring hospitalisation · children with chronic asthma
The intervention showed no clear difference in number of participants with exacerbations requiring hospitalisation (moderate certainty).
1 finding from 1 review
Intervention not reported
Serious adverse events · children with chronic asthma
The intervention showed no clear difference in serious adverse events (moderate certainty).
1 finding from 1 review